Results 211 to 220 of about 40,821 (327)

Azole Endothelin Antagonists. 1. A Receptor Model Explains an Unusual Structure−Activity Profile

, 1996
Thomas W von Geldern, Charles W. Hutchins, Jeffrey A. Kester, Jinshyun R. Wu‐Wong, William J. Chiou, Douglas B. Dixon, Terry J. Opgenorth   +6 more
openalex   +1 more source

The effects of TBC3214, a selective endothelin ETA receptor antagonist, on orthodontic tooth movement in rats [PDF]

, 2007
Špela Sprogar, J. Volk, Martina Drevenšek, Gorazd Drevenšek   +3 more
openalex   +1 more source

Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research

British Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 58-72, January 2026.
Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia.
Titiaan E. Post, Cayla Denney, Adam Cohen, Jens Jordan, Ulrich Limper   +4 more
wiley   +1 more source

EFFECTS OF COMBINED RIOCIGUAT AND ENDOTHELIN RECEPTOR ANTAGONIST THERAPY IN CHINESE PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

Anqi Duan, Zhihua Huang, Zhihui Zhao, Qing Zhao, Xin Li, Sicheng Zhang, Luyang Gao, Qin Luo, Zhihong Liu   +8 more
openalex   +1 more source

Pharmacological Properties of J-104132 (L-753,037), a Potent, Orally Active, Mixed ETA/ETB Endothelin Receptor Antagonist

, 1999
M. Nishikibe, Hisashi Ohta, Megumu Okada, Kinji Ishikawa, Takashi Hayama, Takahiro Fukuroda, Kazuhito Noguchi, Michiyasu Saito, Takeshi Kanoh, Satoshi Ozaki, Tomoe Kamei, Kaori Hara, D. William, Salah D. Kivlighn, Stephen M. Krause, Robert A. Gabel, Gloria J. Zingaro, Nancy A. Nolan, John T. O’Brien, Franklin C. Clayton, Joseph J. Lynch, Douglas J. Pettibone, Peter K. S. Siegl   +22 more
openalex   +1 more source

Clarifying endothelin type B receptor function [PDF]

, 2006
Pollock, D.M., Schneider, M.P.
core   +1 more source

Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 16-26, January 2026.
Abstract Chronic kidney disease (CKD) is a serious complication occurring in nearly one of three people with type 1 diabetes (T1D). Major therapeutic advances have been made in the management of CKD for people with type 2 diabetes (T2D), thereby improving their kidney, cardiovascular, and survival outcomes.
Katherine R. Tuttle, Linong Ji, Chantal Mathieu, Jonathan Rosen   +3 more
wiley   +1 more source

Neuroprotection afforded by antagonists of endothelin-1 receptors in experimental stroke

, 2012
Octavio Moldes, Tomás Sobrino, Miguel Blanco, Jesús Agulla, David Barral, Pedro Ramos‐Cabrer, José Castillo   +6 more
openalex   +2 more sources

A matter arising: When should inflammatory and autoimmune rheumatic diseases be considered ‘early’?

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Timely recognition of inflammatory and autoimmune rheumatic diseases (IARDs) is important to optimize the early diagnosis with tailored interventions and possible prevention of irreversible organ damage. This narrative review provides an update by summarizing the advances in identifying the early stages of rheumatoid arthritis, systemic sclerosis and ...
Elvis Hysa, Emanuele Gotelli, Carmen Pizzorni, Sabrina Paolino, Alberto Sulli, Vanessa Smith, Rosanna Campitiello, Maurizio Cutolo   +7 more
wiley   +1 more source

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects. [PDF]

Drug Des Devel Ther, 2019
Sidharta PN, Melchior M, Kankam MK, Dingemanse J.   +3 more
europepmc   +1 more source